NewAmsterdam Pharma Company N.V.

announcedW=S@11.50

NAMSSEC EDGARCIK: 0001936258|Frazier Life Sciences

Capital Structure & Economics

Trust SizeN/A

Unit Price$10.00

Warrant Coverage-

Sponsor Promote20%

Implied Equity Architecture

Public Trust Allocation	N/A
Sponsor At-Risk Capital	N/A
Total Underwriting Discount	N/A
Trust Per Unit (Implied)	$10.00
Sponsor Promote Allocation	20%

Deal Lifecycle

IPO PricedDec 20, 2022

SearchingTarget Pending

Maturation Wall

N/A

Announced Target / M&A

Target CompanyNewAmsterdam Pharma
Announced Deal Size$391,000,000

Board & Officers

Michael DavidsonCEO
Forbion Growth Opportunities Fund I Coöperatief U.A.Officer
Forbion Capital Fund IV Coöperatief U.A.Officer
Morningside Venture Investments LimitedOfficer
Wouter Joustra⁽²⁾
Director
Mark C. McKenna⁽³⁾
Director
John W. Smither⁽²⁾
Director
James N. Topper⁽²⁾
Director
Sander Slootweg⁽²⁾
Director
James N. Topper, M.D., Ph.D.⁽²⁾
Director

Syndicate & Advisors

Frazier Life Sciences X, L.P.LEAD
Forbion Growth Opportunities Fund I Coöperatief U.A.LEAD
Morningside Venture Investments LimitedLEAD

Interactive Deal Modeling

Base financial constraints (Trust Size, Warrants, Promote) are pre-loaded into the calculation engines. Proceed to model implied dilution and advisory friction limits.

Dilution Cash Friction